Product Description
Cicletanine is under investigation for the treatment of Diabetes, Hypokalemia, Hyponatremia, and Arterial Hypertension. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cicletanine)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | France
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Hyponatremia|Hypertension|Hypokalemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CHAMP | P2 |
Unknown status |
Hypertension|Hyponatremia|Hypokalemia |
2024-06-01 |
24% |
2008-007455-26 | P2 |
Terminated |
Hypertension, Pulmonary |
2012-01-05 |
|
GS-US-235-0101 | P2 |
Terminated |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2011-10-01 |